HST Global Announces Strategic Alliance for R&D

HST Global Announces a Strategic Alliance with World-Renowned Doctor for Product Research and Development

HAMPTON, Va.--()--HST Global, Inc. (OTCBB: HSTC) today announced a strategic R&D alliance with Dr. James W. Forsythe for the research and development of HST’s exclusive Nutraceutical and Medical Food formulation platform. Dr. Forsythe brings over thirty years of medical and research experience including expertise in the research and clinical application of Nutraceutical and Medical Food products.

"Dr. Forsythe’s well established experience in the medical community will be a valuable asset in the development of our exclusive brand of products," said Ron Howell, CEO and President of HST Global, Inc. "James will be instrumental in the acquisition of new technologies in the emerging field of science-based Nutraceuticals." Dr. Forsythe is a past Associate Professor of Medicine and Pathology, University of Nevada Medical School Reno, NV. Prior to that, he was an instructor in Medicine and Hematology, University of California Medical Center, San Francisco, CA.

Dr. Forsythe currently serves on HST Global Inc.’s Scientific Advisory Board. He received his Doctorate of Medicine from the University of California, San Francisco and his Undergraduate Degree from University of California at Berkeley. Dr. Forsythe is certified in Homeopathy and Board Certified in Internal Medicine, Medical Oncology and Utilization Review and Quality Assurance. He is also Board eligible in Clinical Pathology and Medical Gerontology. Dr. Forsythe is also the owner and Medical Director of Cancer Screening and Treatment Center of Nevada and Century Wellness Clinic. In addition, Dr. Forsythe spent 26 years in the United States Army Medical Corps, retiring full Colonel. He was also the former State Surgeon in the Nevada Army National Guard.

Through a proprietary scientific platform, HST is developing therapies that address metabolic deficiencies through the application of either proprietary or Patent-Pending Nutraceutical technologies, or where appropriate, Medical Food products. Medical Food products are FDA-regulated products, in a relatively new category of medical protocols defined by Congress as part of the Orphan Drug Act. Medical Food products are formulated for administration under the supervision of a physician and are intended for the specific dietary management of a disease or condition based on recognized scientific principles and established by medical evaluation. Medical Foods can be prescription products, but are different than drugs or dietary supplements in several aspects, such as their claims. Claims for both Medical Foods and drugs must be supported by solid laboratory and clinical data.

About HST Global, Inc.

HST Global, Inc. is an Integrated Biotechnology Health and Wellness company that is developing and or acquiring a network of Wellness Centers worldwide that are primarily focused on the immunotherapy and alternative treatment of late stage cancer. In addition, the company intends to acquire innovative products for the treatment of late stage cancer. In this regard, the company primarily focuses on immunotherapy and alternative product candidates that are undergoing or have already completed significant clinical testing for the treatment of late stage cancer.

HST Global, Inc. wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials by others; possible acquisitions of other technologies, assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.

Contacts

HST Global, Inc.
Investor Relations:
David Nesbitt, 757-766-6100
ir@hstglobal.com
www.hstglobal.com

Contacts

HST Global, Inc.
Investor Relations:
David Nesbitt, 757-766-6100
ir@hstglobal.com
www.hstglobal.com